Synonyms: zanidatamab-hrii | Ziihera® | ZW-25 | ZW25
zanidatamab is an approved drug (DA (2024))
Compound class:
Antibody
Comment: Zanidatamab (ZW25) is an anti-ERBB2 (HER2) monoclonal antibody [3]. It is biparatopic, meaning that it interacts with two independent extracellular epitopes on the ERBB2 receptor. Antibody binding induces ERBB2 internalisation, as well as CDC, ADCC and ADCP. The two epitopes are those bound by trastuzumab (ECD4) and pertuzumab (ECD2). Zanidatamab was designed to treat ERBB2 over-expressing advanced solid tumours, in particular types other than breast cancer [4].
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2024) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10997 | zanidatamab |
Synonyms ![]() |
zanidatamab-hrii | Ziihera® | ZW-25 | ZW25 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 735 |
Other databases | |
GtoPdb PubChem SID | 504705446 |
Search PubMed clinical trials | zanidatamab |
Search PubMed titles | zanidatamab |
Search PubMed titles/abstracts | zanidatamab |